Exelixis (EXEL) Competitors

Medpace (NASDAQ:MEDP) and Exelixis (NASDAQ:EXEL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Which has more volatility and risk, MEDP or EXEL?

Medpace has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Does the MarketBeat Community believe in MEDP or EXEL?

Exelixis received 247 more outperform votes than Medpace when rated by MarketBeat users. Likewise, 68.54% of users gave Exelixis an outperform vote while only 63.77% of users gave Medpace an outperform vote.

Company	Underperform	Outperform
Medpace	Outperform Votes 352 63.77%	Underperform Votes 200 36.23%
Exelixis	Outperform Votes 599 68.54%	Underperform Votes 275 31.46%

Do analysts recommend MEDP or EXEL?

Medpace presently has a consensus price target of $380.00, indicating a potential upside of 16.53%. Exelixis has a consensus price target of $31.44, indicating a potential downside of 9.25%. Given Medpace's higher possible upside, analysts plainly believe Medpace is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.45
Exelixis	1 Sell rating(s)	5 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.65

Which has preferable earnings and valuation, MEDP or EXEL?

Medpace has higher earnings, but lower revenue than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$1.89B	5.37	$282.81M	$11.42	28.55
Exelixis	$2.08B	4.75	$207.76M	$1.56	22.21

Is MEDP or EXEL more profitable?

Exelixis has a net margin of 22.43% compared to Medpace's net margin of 17.66%. Medpace's return on equity of 50.87% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.66%	50.87%	19.61%
Exelixis	22.43%	20.99%	16.07%

Do institutionals & insiders have more ownership in MEDP or EXEL?

78.0% of Medpace shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 20.3% of Medpace shares are owned by company insiders. Comparatively, 2.9% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the media refer more to MEDP or EXEL?

In the previous week, Exelixis had 2 more articles in the media than Medpace. MarketBeat recorded 10 mentions for Exelixis and 8 mentions for Medpace. Exelixis' average media sentiment score of 0.91 beat Medpace's score of 0.36 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exelixis	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Medpace and Exelixis tied by winning 9 of the 18 factors compared between the two stocks.